Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABEO POWR Grades
- Sentiment is the dimension where ABEO ranks best; there it ranks ahead of 67.37% of US stocks.
- ABEO's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- ABEO ranks lowest in Stability; there it ranks in the 4th percentile.
ABEO Stock Summary
- ABEO's went public 35.45 years ago, making it older than 92.79% of listed US stocks we're tracking.
- ABEO's price/sales ratio is 16.73; that's higher than the P/S ratio of 88.27% of US stocks.
- As for revenue growth, note that ABEO's revenue has grown 42.86% over the past 12 months; that beats the revenue growth of 87.52% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Abeona Therapeutics Inc, a group of peers worth examining would be ALBO, KALA, VIVE, CLSN, and MRAM.
- ABEO's SEC filings can be seen here. And to visit Abeona Therapeutics Inc's official web site, go to www.abeonatherapeutics.com.
ABEO Price Target
For more insight on analysts targets of ABEO, see our ABEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.67 | Average Broker Recommendation | 1.33 (Strong Buy) |
ABEO Stock Price Chart Interactive Chart >
ABEO Price/Volume Stats
| Current price | $1.82 | 52-week high | $3.79 |
| Prev. close | $1.85 | 52-week low | $0.99 |
| Day low | $1.79 | Volume | 832,200 |
| Day high | $1.89 | Avg. volume | 3,055,881 |
| 50-day MA | $1.62 | Dividend yield | N/A |
| 200-day MA | $1.76 | Market Cap | 180.21M |
Abeona Therapeutics Inc. (ABEO) Company Bio
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.
Latest ABEO News From Around the Web
Below are the latest news stories about Abeona Therapeutics Inc that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
Abeona Therapeutics to Present at Jefferies Virtual Healthcare ConferenceNEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 a.m. ET. A live and archived webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. About Abeona |
Abeona Therapeutics shares rise after letter to stockholdersAbeona Therapeutics shares rise ([[ABEO]] +6.7%) after the company listed out its achievements during 2020, and provided an update to its strategic goals for the remainder of the current year.In a letter to the company's stockholders, it highlighted some of Abeona's key milestones in 2020:The initiation of a late-stage study... |
Abeona Therapeutics Issues Letter to StockholdersNEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in conjunction with the 2021 Abeona Therapeutics Annual Meeting of Stockholders to be held today, May 26, 2021: Dear Fellow Stockholders, We at Abeona remain committed to bringing urgently needed treatments to patients with recessive dystrophic epidermolysis bullosa (RDEB), and Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB, respectively). I am incredibly proud of the tremendous progress Abeona achieved in 2020 and to start 2021, which is a testament to the talent, unwavering commitment, and ability to execute of our employees, who have worked tirelessly to achieve important miles... |
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q1 2021 Results - Earnings Call TranscriptAbeona Therapeutics Inc. (ABEO) Q1 2021 Earnings Conference Call May 25, 2021 08:30 ET Company Participants Gregory Gin - Vice President, Investor Relations and Corporate Communications Michael Amoroso - Chief Executive Officer Ed Carr - Chief Accounting Officer Juan Ruiz - Vice President Brian Kevany - Lead Research Scientist Conference... |
Abeona Therapeutics Appoints Head of Research & Clinical DevelopmentNEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas Seshadri, Ph.D., M.B.A., as Senior Vice President, Head of Research & Clinical Development, effective June 1, 2021. Dr. Seshadri joins the company from Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS), and brings more than 20 years of experience including in academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell therapies. “I am very excited to announce Vish as our new Head of Research & Clinical Devel... |
ABEO Price Returns
| 1-mo | 31.88% |
| 3-mo | -21.21% |
| 6-mo | 13.75% |
| 1-year | -38.10% |
| 3-year | -88.55% |
| 5-year | -38.51% |
| YTD | 15.92% |
| 2020 | -51.99% |
| 2019 | -54.20% |
| 2018 | -54.95% |
| 2017 | 226.80% |
| 2016 | 44.35% |
Continue Researching ABEO
Want to see what other sources are saying about Abeona Therapeutics Inc's financials and stock price? Try the links below:Abeona Therapeutics Inc (ABEO) Stock Price | Nasdaq
Abeona Therapeutics Inc (ABEO) Stock Quote, History and News - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...